A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.

被引：23
|
作者：
Javle, Milind M. [1 ]
Bridgewater, John A. [2 ]
Gbolahan, Olumide B. [3 ]
Jungels, Christiane [4 ]
Cho, May Thet [5 ]
Papadopoulos, Kyriakos P. [6 ]
Thistlethwaite, Fiona C. [7 ,8 ]
Canon, Jean-Luc Re [9 ]
Cheng Lulu [10 ]
Ioannidis, Sonia [10 ]
Gogov, Sven [10 ]
Aung, Naing [11 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] UCL, Inst Canc, London, England
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[5] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[6] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[7] Dept Med Oncol, Manchester, Lancs, England
[8] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[9] Grand Hop Charleroi, Dept Hematol Oncol, Charleroi, Belgium
[10] Incyte Corp, Wilmington, DE USA
[11] Univ Texas MD Anderson Canc Ctr, Phase Program 1, Dept Invest Canc Therapeut, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
311
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
    Evans, T. R. Jeffry
    Wylie, Eileen
    Garcia, Jorge Curto
    Coxon, Fareeda
    Wall, Lucy
    Eatock, Martin
    Maughan, Tim
    Highley, Martin
    Zimmerli, Priska Butzberger
    ANNALS OF ONCOLOGY, 2006, 17 : 320 - 320
  • [22] Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC)
    Cleary, James M.
    Voss, Martin Henner
    Meric-Bernstam, Funda
    Hierro, Cinta
    Heist, Rebecca Suk
    Ishii, Nobuya
    Kirpicheva, Yulia
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Vaslin, Anne
    Venetz, Werner
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [23] A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers.
    Blagden, Sarah Patricia
    Rizzuto, Ivana
    Stavraka, Chara
    O'Shea, Daniel
    Suppiah, Puvan
    Patel, Markand
    Loyse, Naomi
    Sukumaran, Ajithkumar
    Bharwani, Nishat
    Rockall, Andrea
    Gabra, Hani
    El-Bahrawy, Mona
    Wasan, Harpreet S.
    Leonard, Robert C. F.
    Habib, Nagy A.
    McGuigan, Christopher
    Gribben, John G.
    Ghazaly, Essam Ahmed
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] A multicenter phase II study of gemcitabine plus S-1 chemotherapy for advanced biliary tract cancer
    Arima, S.
    Shimizu, K.
    Okamoto, T.
    Toki, S.
    Kasuga, A.
    Kitamura, H.
    Takasu, A.
    Nagashima, F.
    Sugiyama, M.
    Furuse, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S627 - S627
  • [25] A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer
    Arima, Shiho
    Shimizu, Kyoko
    Okamoto, Tomoyoshi
    Toki, Masao
    Suzuki, Yutaka
    Okano, Naohiro
    Naruge, Daisuke
    Kawai, Kirio
    Kobayashi, Takaaki
    Kasuga, Akiyoshi
    Kitamura, Hiroshi
    Takasu, Atuko
    Nagashima, Fumio
    Sugiyama, Masanori
    Furuse, Junji
    ANTICANCER RESEARCH, 2017, 37 (02) : 909 - 914
  • [26] A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer
    Zhou, Mingzhen
    Jin, Yuncheng
    Zhu, Sihui
    Xu, Chen
    Li, Lin
    Liu, Baorui
    Shen, Jie
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (01)
  • [27] A randomized phase II study of gemcitabine (GEM) plus S-1 combination chemotherapy versus GEM monotherapy in patients (pts) with advanced biliary tract cancer (BTC)
    Sasaki, T.
    Isayama, H.
    Ito, Y.
    Yasuda, I.
    Toda, N.
    Hanada, K.
    Matsubara, S.
    Maoguchi, H.
    Yashlma, Y.
    Kamada, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [28] A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers.
    Papadatos-Pastos, Dionysios
    Kumar, Rajiv
    Yap, Timothy Anthony
    Ruddle, Ruth
    Decordova, Shaun
    Jones, Paul
    Halbert, Gavin
    Garrett, Michelle D.
    McLeod, Robert
    Backholer, Zoe
    Swales, Karen E.
    Raynaud, Florence I.
    De Bono, Johann Sebastian
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)
    Kim, R.
    Kim, D.
    Alese, O.
    Li, D.
    El-Rayes, B.
    Shah, N.
    Schell, M.
    Zhou, J.
    Chung, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
    Kim, Richard D.
    Joseph-Ridge, Nancy
    Du, Jichang
    North, Janine
    Warren, Cathy
    Iyer, Renuka V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 472 - 472
12345